2025 Volume 14 Issue 1 Pages 6-11
CD19-directed chimeric antigen receptor (CAR) T-cell therapy represents a paradigm shift in the treatment of relapsed or refractory large B-cell lymphoma. However, the published real-world outcomes in European (EU) cohorts are inferior to those in the United States (US). One factor contributing to this difference is that the average time between leukapheresis and CAR T-cell infusion, known as the vein-to-vein interval, is longer for patients treated in the EU than for those treated in the US. The vein-to-vein interval in Japan is longer than that in the EU and is expected to extend beyond 2022. This presents an important issue that must be immediately addressed. After leukapheresis, some patients do not receive CAR T-cell infusion because of disease progression or complications. Unused apheresis product leads to a loss of treatment opportunities and financial burden. The optimization of hospital bed management, bridging therapies, and infection control is essential for resolving these problems.
